Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2019 · 10-Q
Revenue$36.85K$36.85K−67.0% vs Q2 2018 Net Income-$4.13M-$4.13MN/M vs Q2 2018 EPS Diluted-$0.79-$0.79N/M vs Q2 2018 Operating Income-$4,219,959N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,443,113N/M Margins · derivedOperating margin-11451.1%−7480.5 pt vs Q2 2018
Net margin-11194.2%−7843.2 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 8, 2019 · 39 d after period end